Atezolizumab ( Tecentriq ) was the first cancer immunotherapy approved by the FDA for people with advanced bladder cancer and has become a standard of care in those whose disease has progressed after receiving other medicines, either before or after surgery, or after their disease has spread.
-
-

Cancer immunotherapy: Tecentriq approved in advanced bladder cancer as initial treatment for those unable to receive Cisplatin chemotherapy

The US Food and Drug Administration ( FDA ) has granted accelerated approval to Tecentriq ( Atezolizumab ) for the treatment of people with locally advanced or metastatic urothelial carcinoma ( mUC ) …